By Colin Kellaher
Merck & Co. is licensing a potential oral obesity drug from Hansoh Pharma in a deal potentially worth more than $2 billion to the Chinese biopharmaceutical company.
Merck on Wednesday said it will make an upfront payment of $112 million to Hansoh in exchange for an exclusive global license to HS-10535, an investigational small-molecule GLP-1 receptor agonist.
The Rahway, N.J., drugmaker said Hansoh also is eligible to receive up to $1.9 billion in milestone payments, along with royalties on product sales.
GLP-1 drugs, which work in part by mimicking a gut hormone to suppress appetite and make users feel full, are used to treat both Type 2 diabetes and obesity. These include the blockbuster injectable drugs Ozempic and Wegovy from Novo Nordisk and Mounjaro and Zepbound from Eli Lilly, and pharmaceutical companies are racing to break into the burgeoning sector with weight-loss pills.
Merck said it plans to evaluate HS-10535's potential to provide additional cardiometabolic benefits beyond weight loss.
The company said it will post a fourth-quarter charge of four cents a share related to the Hansoh deal.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 18, 2024 07:24 ET (12:24 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。